Wiley-VCH announces next year's launch of Proteomics - Clinical Applications (PCA), a new journal in the field of applying proteomics to the study of human disease and translation to the clinic
"After just six years, Proteomics - the parent journal - has already achieved an excellent impact factor of 6.088 (ISI 2005) and been able to further strengthen its market position as the leading international source for information on all aspects in proteomics.
"Now, as a result of this enormous success, Proteomics - Clinical Applications (PCA) is to be published as a stand-alone journal starting in 2007.
"With 12 issues a year, PCA will focus on clinical research, including dysfunction in human disease, validation of diagnostic and prognostic disease biomarkers, novel drug targets and clinical trials.
"We hope that those working in the area of clinical proteomics will choose Proteomics - Clinical Applications as the premier place in which to publish the results of their research and the definitive forum for keeping abreast of developments in this field," explained Michael Dunn, editor-in-chief of Proteomics.
He was also quick to point that "it will continue to be important for those in the field to continue to read the parent journal, as Proteomics will continue to publish papers relevant to biomedicine".
News of the launch has already met with much enthusiasm among the scientific community, says the publisher, with editors from around the world praising both the idea and the concept.
Proteomics - Clinical Applications, will target clinical researchers, researchers in the pharmaceutical industry, biochemists, clinical chemists, immunologists, geneticists, and molecular biologists interested in mechanisms of disease, as well as toxicologists.
PCA will be available in print and online via Wiley InterScience.
